Radiant Sage Expands to Europe
Radiant Sage has partnered with Oslo, Norway-based imaging CRO Clearpoint Image Review Center to provide expanded imaging operations.
Radiant Sage, a clinical trial imaging solutions and services provider, announced that it has expanded its operations into Europe through its partnership with Oslo, Norway-based imaging CRO Clearpoint Image Review Center (CIRC).
CIRC will provide the facility and staffing resources for program management-based support for clinical studies in both the EU and U.S. They will also offer a wide range of services, including: audit support, document development and reader logistics to clinical study sponsor communications, site support and metrics reporting. In addition, CIRC will be able to leverage Radiant Sage's technology, staff and resources to support clients' clinical research studies.
Read the full release.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
